Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer

Introduction: The mutation rate of T790M might change the effective therapeutic sequence of EGFR tyrosine kinase inhibitors (TKIs). This simulation estimates the T790M positivity rate required for first-line first- or second-generation EGFR TKI to exceed overall progression-free survival (PFS) of fi...

Full description

Bibliographic Details
Main Authors: Naoki Haratake, MD, PhD, Toshihiro Misumi, PhD, Takeharu Yamanaka, PhD, Takashi Seto, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
EGFR
Sequential treatment
Rebiopsy
T790M
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301089

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301089

Similar Items